



Lantheus Holdings to Present at the BMO 2020 Prescriptions for Success Virtual Healthcare Conference

June 16, 2020

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Jun. 16, 2020-- [Lantheus Holdings, Inc.](#) (the "Company") (NASDAQ: LNTH), the parent company of [Lantheus Medical Imaging, Inc.](#) ("LMI"), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced Mary Anne Heino, President and Chief Executive Officer, will present at the BMO 2020 Prescriptions for Success Virtual Healthcare Conference at 3:30 p.m. ET on Tuesday, June 23.

To access a live webcast of the presentation, please visit the [Investors](#) section of the Company's website at www.lantheus.com. A replay of the webcast will be available on the Company's website for 30 days following the live presentation.

About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.

Lantheus Holdings, Inc. is the parent company of LMI, a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, including the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension and TechnoLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico and Canada. For more information, visit www.lantheus.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20200616005336/en/>

Mark Kinarney
978-671-8842
ir@lantheus.com

Source: Lantheus Holdings, Inc.